These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1199 related articles for article (PubMed ID: 27140411)

  • 1. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
    Karim S; Leighl N
    Future Oncol; 2016 Jan; 12(1):9-23. PubMed ID: 26631501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
    Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
    J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
    Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
    Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.
    Loo K; Daud A
    Immunotherapy; 2016 Jun; 8(7):775-84. PubMed ID: 27349977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
    Jørgensen JT
    Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
    Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
    Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.